Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The Acute Effect of Resistance Exercise in Individuals With Hypertrophic Cardiomyopathy: A Pilot Study.

The American journal of cardiology·2026
Same author

Prevalence and Predictors of Cardiac Troponin Elevations Following Exercise: a Systematic Review, Meta-analysis, and Meta-regression.

European journal of preventive cardiology·2026
Same author

Sudden Cardiac Arrest in Athletes.

The New England journal of medicine·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026
Same author

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Syncope During Cycling.

JACC. Case reports·2026

関連する実験動画

Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

スタチン関連ミオパシー

Paul D Thompson1, Priscilla Clarkson, Richard H Karas

  • 1Preventive Cardiology and Cardiovascular Research, Division of Cardiology, Hartford Hospital, Hartford, Conn 06102, USA. pthomps@harthosp.org

JAMA
|April 4, 2003
PubMed
まとめ
この要約は機械生成です。

スタチンは,軽度の痛みから重度のラブドミオリシスまで,筋肉の問題を引き起こす可能性があります. 危険因子と薬物相互作用は,これらの有害効果を増加させることができ,そのメカニズムはまだ調査中です.

関連する実験動画

Last Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

科学分野:

  • 薬理学 薬理学とは
  • 毒理学 毒理学 毒理学
  • クリニカル・メディシン 臨床医学

背景:

  • HMG-CoA還元酵素阻害剤であるスタチンは,コレステロール管理に広く使用されています.
  • これらの薬は,骨格筋の苦情のスペクトルと関連しており,筋痛からラブドミオリシスまで様々です.
  • これらの副作用を理解することは,患者の安全性と効果的な脂質低下療法にとって極めて重要です.

研究 の 目的:

  • スタチン関連筋痛症の臨床概要を提供するために.
  • スタチン誘発の筋肉損傷の潜在的メカニズムについて議論します.
  • FDAのデータを用いて,スタチン関連性ラブドミオリシスに関する報告を更新する.

主な方法:

  • PubMed (2002年11月まで) によるスタチンミオパシーに関する論文の文献レビュー.
  • スタチンの臨床試験,ケースシリーズ,レビューのレビュー (2003年1月までのPubMed).
  • スタチン関連ラブドミオリシスに関するFDA MEDWATCHの有害事象報告の分析 (1990年1月 - 2002年3月).

主要な成果:

  • スタチンの臨床試験では筋肉の問題はまれである.
  • FDAのMEDWATCHシステムでは,スタチン関連のラブドミオリスの3339例が記録されており,セリバスタチンは最も関与している.
  • 軽度の筋肉症状 (痛み,弱さ) に関するデータは,1~5%の有病率を示唆し,危険因子や薬物相互作用 (ゲンフィブロジルなど) は副作用を悪化させる可能性があります.

結論:

  • スタチン関連ミオパシーは,希少だが重度のラブドミオリシスを含む一連の筋肉問題を含む.
  • 臓器機能不全,併発症,薬物相互作用などの要因は,骨髄病のリスクに大きな影響を与えます.
  • 仕組みは完全に解明されていませんが,スタチンは,調節性タンパク質の産生を減少させることで,肌細胞維持を損なう可能性があります.